comparemela.com

Latest Breaking News On - Professor harish nair - Page 1 : comparemela.com

Government urged to roll out virus jab for babies or face a wave of sick infants in the coming winter

It has been nearly a year since an advisory group recommended an immunisation against respiratory syncytial virus - best known for causing the lung infection bronchiolitis in children.

Cold virus killed 100,000 children globally in 2019

Nearly half the deaths from respiratory syncytial virus were in babies aged under six months.

RSV signs to look out for as common virus kills 100,000 under 5s every year

RSV signs to look out for as common virus kills 100,000 under 5s every year
mylondon.news - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mylondon.news Daily Mail and Mail on Sunday newspapers.

Indian-origin experts urge UK to back patent waiver for vaccine parity

Several Indian-origin scientists are among hundreds of worldwide experts to urge the UK to back a temporary waiver of intellectual property rules for Covid-19 vaccines, tests, and treatments at the World Trade Organisation (WTO) to achieve greater vaccine parity worldwide. India and South Africa had introduced a proposal at the WTO for such a patent waiver for fairer vaccine

The real cost of RSV, a common but often fatal disease

The real cost of RSV, a common but often fatal disease RESCEU have put together the most comprehensive cache of evidence to date on the true burden of a disease that still claims millions of mostly infant victims every year  Image by Blanscape via Shutterstock   Anyone can catch respiratory syncytial virus, and most people are infected before their fifth birthday. Symptoms can vary from mild to deadly. Young children are at greatest risk, though it can also be serious for older people and those with other health problems. To try to get the full picture of how much of an impact the disease has on populations and public health systems, a team of researchers, policy makers, pharma sector representatives and patient advocates came together under the RESCEU project to produce an evidence-based tally of the costs of the disease, with the ultimate aim of using the data to feed public health strategies.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.